Kabra Drugs Ltd. significantly lags behind its peers in all key financial metrics, displaying zero growth, profitability, and efficiency. In contrast, companies like Sun Pharma and Cipla show robust growth and profitability, highlighting the challenges faced by Kabra Drugs in a competitive market.

• • Kabra Drugs Ltd. shows no revenue growth or profitability metrics, with a PE ratio of -39.84 indicating losses.
• • Sun Pharmaceutical Industries and Cipla Ltd. emerge as strong performers with excellent revenue growth and profitability ratios.
• • Kabra Drugs has a debt-to-equity ratio of 0, indicating no debt but also raising concerns about potential growth opportunities.